Neurocrine Biosciences, Inc. - Common Stock (NBIX)
137.45
-0.57 (-0.41%)
NASDAQ · Last Trade: Oct 30th, 12:52 PM EDT
Detailed Quote
Previous Close
138.02
Open
137.41
Bid
137.40
Ask
137.68
Day's Range
136.51 - 140.19
52 Week Range
84.23 - 154.61
Volume
334,865
Market Cap
13.70B
PE Ratio (TTM)
32.88
EPS (TTM)
4.2
Dividend & Yield
N/A (N/A)
1 Month Average Volume
927,356
Chart
About Neurocrine Biosciences, Inc. - Common Stock (NBIX)
Neurocrine Biosciences is a biopharmaceutical company focused on developing innovative treatments for neurological and endocrine diseases. The company conducts research and creates drug therapies aimed at addressing the unmet medical needs of patients suffering from conditions such as movement disorders, psychiatric disorders, and hormonal disorders. Through a combination of scientific expertise and cutting-edge technology, Neurocrine strives to enhance patient outcomes and improve quality of life, while expanding its pipeline of therapeutic options in the field of neuroscience and endocrinology. Read More
Neurocrine Biosciences (NBIX) is a strong value stock with a debt-free balance sheet, high profitability, and solid growth, trading at a discount to its industry peers.
Neurocrine Biosciences (NBIX) smashed Q3 2025 earnings estimates, with a 26% EPS beat and strong revenue growth driven by its flagship product INGREZZA®.
A powerful surge in AI-related stocks — led by a 9% advance in NVIDIA Corp. (NASDAQ:NVDA) over the past two sessions — propelled the S&P 500 above the 6,900 mark and lifted the Nasdaq 100 to 26,100 points, both breaking new records, as investors brace for the Federal Reserve's
Discover Neurocrine Biosciences (NBIX), an affordable growth stock with strong financials, solid profit margins, and a promising pipeline in neuroscience treatments.
Gainers PepGen (NASDAQ: PEPG) shares rose 141.0% to $6.41 during Thursday's pre-market session. The market value of their outstanding shares is at $87.2 million.
Neurocrine Biosciences (NBIX) offers solid growth and strong profitability at a reasonable valuation. This biotech stock fits the "affordable growth" strategy for long-term investors.
Neurocrine Biosciences (NBIX) shows strong growth potential with solid fundamentals, high profitability, and a bullish technical breakout pattern in the biotech sector.
